Immunotherapy drug bolsters head and neck cancer treatment
A clinical trial has shown that the immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk.
Materials provided by University of Cincinnati. Original written by Tim Tedeschi. Note: Content may be edited for style and length.
Source link aaaaa